Insulin Applications Intended For Biosimilar Pathway May Already Be At US FDA
Executive Summary
In congressional testimony, outgoing Commissioner Scott Gottlieb says FDA already has "a lot of applications in-house" and robust interest when asked about the 2020 transition of insulin from regulation as a drug to a biologic.
You may also be interested in...
Senate Wants Priority Review For 'Deemed' Biologics Not Approved By Deadline
Appropriations report directs the US FDA to offer the faster assessment and allow reliance on prior data submitted for applications caught in the transition from drug to biologic regulation.
Biosimilar User Fee Collections Drop Below Estimates, But FDA Is Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.
Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.